Biology subjects

Lavallee, V.-P.

Publications and source records attributed to Lavallee, V.-P..

10 recordsLinked to original sources

bioRxiv2025

Unveiling the temporal impact: Exploring dynamic changes in the paediatric solid tumour immune microenvironment through time

The composition of the tumour immune microenvironment (TIME) influences tumour evolution and responsiveness to immunotherapy. While longitudinal changes in TIME have been well-characterized in adult cancers, its dynamics in childhood cancers remain poorly documented, limiting our ability to predict treatment responses and tailor immunotherapeutic strategies. This study aimed to evaluate the plasticity of TIME in paediatric solid tumours, investigate its longitudinal evolution, and identify time-dependent immune alterations. Transcriptomic data from longitudinal samples of 27 paediatric patients (<21 years old) with relapsed or refractory solid tumours were analysed, encompassing 70 timepoints: 16 diagnoses and 54 successive relapses. TIME plasticity was assessed using gene expression clustering and immune cell infiltration enumeration. Patient-adjusted longitudinal analyses were performed using generalised linear mixed models (glmmSeq), adjusted for age and sex. Temporal associations of immune changes were further explored using dynamic regression models. Thirteen patients exhibited significant changes in their TIME profile, indicating high TIME plasticity. Over time, the TIME shifted toward a tolerogenic and immunosuppressive state, characterised by decreased activity in immune pathways (e.g., T cell receptor signalling) and enrichment of tolerogenic (e.g., macrophage differentiation) and oncogenic pathways (e.g., IL6-JAK-STAT3). The core enrichment of upregulated pathways contained key immunosuppressive factors: immune checkpoints (CTLA-4), tumour-associated macrophage activators (CSF1/CSF1R), T-regulatory cell activators (TGFB1), and immunosuppressive genes (IL10RA). This study provides evidence that the TIME in paediatric solid tumours is plastic and remodels towards immune depletion and tolerogenicity. This evolution may underlie treatment resistance and disease progression, underscoring the need for TIME-informed therapeutic approaches in paediatric oncology. Significance StatementThis article demonstrates the plasticity of the tumour immune micro-environment (TIME) of paediatric solid tumours throughout disease evolution. Longitudinal transcriptomic analyses of 70 tumour samples from 27 patients showed a progressive remodelling towards tolerogenicity and immune depletion. Key immunosuppressive factors, including immune checkpoints and tumour-associated macrophages, were identified as potential contributors to immune escape. These findings support the relevance of longitudinal immune monitoring in paediatric oncology and may inform future strategies for immunotherapeutic interventions.

cancer biology↗

bioRxiv2025

TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition

TP53-mutated acute myeloid leukemia (AML) represents a particularly aggressive and therapeutically refractory subtype of the disease. While recurrent chromosomal abnormalities such as -5/del(5q), -7/del(7q), and del(17p) are well studied in this context, additional co-occurring events remain less well defined. Using the multi-dimensional Leucegene dataset ([~]700 primary AML specimens), we identified and comprehensively characterized a distinct subset of TP53-altered AML marked by recurrent deletions on the short arm of chromosome 3 (del(3p), > 20% TP53-mutated cases). These deletions frequently co-occur with del(5q) and encompass several ribosomal protein genes (RPGs), leading to a global downregulation of the ribosomal network and reduced protein synthesis. We show that this ribosomopathy-like phenotype is most pronounced in TP53-mutated cases with combined RPG deletions on chromosomes 3p and 5q, suggesting a cooperative oncogenic mechanism. Importantly, chemical screening identified HSP90 inhibition as a selective vulnerability in AML with low RPG expression. These findings highlight a previously unappreciated TP53-altered AML subset characterized by converging genomic and translational defects, and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.

cancer biology↗

bioRxiv2025

Predictive Gene Discovery with EPCY: A Density-Based Alternative to DE analysis

Identifying predictive genes from high-throughput data remains a key challenge in biomedical research. Most current approaches rely on statistical tests to select differentially expressed genes (DEGs), which may not align with the goal of predicting outcomes. We present EPCY, a method that ranks genes based on their predictive power using cross-validated classifiers and density estimation, without relying on null hypothesis testing. Applied to both bulk and single-cell RNA sequencing datasets, EPCY consistently outperforms benchmark DEG-based methods in selecting robust candidate genes. It also demonstrates greater stability across varying cohort sizes, enabling reproducible gene prioritization even in large, heterogeneous datasets. EPCY provides interpretable predictive scores, facilitating candidate selection aligned with downstream validation goals.

bioinformatics↗

bioRxiv2025

Inhibition of IL2Rβ-dependent STAT5 activity supports T-cell stemness and augments antitumor efficacy of CD8+ T cells by preventing T-cell exhaustion

CD8+ T-cell exhaustion is a leading cause of adoptive cell therapy (ACT) failure. In contrast, maintaining a stem-like state correlates with better expansion, persistence, and anti-tumor activity of infused T-cell products. IL-2 is extensively used in ACT protocols given its ability to expand T-cell populations. Yet, IL-2 drives more differentiated and exhausted states, diminishing the quality of T-cell products. Understanding how cytokines of the IL2R family drive T-cell differentiation is essential to ultimately design optimal ACT protocols, safeguarding stem-like programs while ensuring sufficient T-cell expansion. Here, we show that cytokine signaling through IL2R{beta} supports more differentiated exhausted T cells in chronic lymphocytic choriomeningitis infection. Similarly, high levels of IL-2 and IL-15 in vitro foster heightened differentiation and exhaustion of cells for adoptive cell therapy. In contrast, absence of IL2R{beta} in vivo or transient inhibition of Janus kinase 3 (JAK3) or signal transducer and activator of transcription 5 (STAT5) in vitro favors features of T-cell stemness. Transcriptional analyses of in vitro expanded T cells further reveal that inhibition of STAT5 sustains a stemness program, which correlates with better antitumor activity in a mouse melanoma model. When applied to a human CAR T expansion model, inhibition of STAT5 supports memory progenitor differentiation and limit inhibitory receptor expression. These results demonstrate that continuous exposure to high levels of cytokines, such as IL-2 and IL-15, constrain CD8+ T cells towards more advanced states of exhaustion. In contrast, limiting cytokine signaling using specific kinase inhibitors preserves stem-like T-cell programs and enhance the quality of ACT products. One Sentence SummarySustained IL-2/IL-15 signaling drives CD8+ T-cell exhaustion while JAK3/STAT5 inhibition preserves stemness, boosting adoptive cell therapy efficacy.

immunology↗

bioRxiv2025

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes

The t(6;9)(p22.3;q34.1) translocation/DEK::NUP214 fusion protein defines a distinct subgroup of younger AML patients classified as a separate disease entity by the World Health Organization. DEK is a nuclear factor with multifunctional roles, including gene regulation, while its fusion partner, NUP214, plays a pivotal role in nuclear export by interacting with transport receptors such as XPO1. However, the precise mechanism by which DEK::NUP214 drives leukemia remains unclear. A comprehensive multi-omics comparison of 57 AML primary samples (including whole genome sequencing, targeted sequencing, transcriptomics, and drug screening with > 500 compounds) revealed that t(6;9) cases display a selective response to XPO1 inhibitors (Selinexor & Eltanexor) and a distinct transcriptomic signature characterized by the overexpression of FOXC1 and HOX genes that are key leukemia mediators. CUT&RUN experiments demonstrated the direct binding of DEK::NUP214 to the promoters of FOXC1 and HOXA/B clusters. Strikingly, the expression of these genes and the binding of DEK::NUP214 to their regulatory regions were selectively reduced upon XPO1 inhibition in t(6;9) cells. Altogether, these results identified a novel function of DEK::NUP214 as an XPO1-dependent transcriptional activator of key leukemia drivers and provide a rationale to explore the use of XPO1 inhibitors in this patient population.

cancer biology↗

bioRxiv2023

Deep generative model deciphers derailed trajectories in acute myeloid leukemia

Biological insights often depend on comparing conditions such as disease and health, yet we lack effective computational tools for integrating single-cell genomics data across conditions or characterizing transitions from normal to deviant cell states. Here, we present Decipher, a deep generative model that characterizes derailed cell-state trajectories. Decipher jointly models and visualizes gene expression and cell state from normal and perturbed single-cell RNA-seq data, revealing shared and disrupted dynamics. We demonstrate its superior performance across diverse contexts, including in pancreatitis with oncogene mutation, acute myeloid leukemia, and gastric cancer.

bioinformatics↗

bioRxiv2022

Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain

Neutralizing antibodies (NAbs) hold great promise for clinical interventions against SARS-CoV- 2 variants of concern (VOCs). Understanding NAb epitope-dependent antiviral mechanisms is crucial for developing vaccines and therapeutics against VOCs. Here we characterized two potent NAbs, EH3 and EH8, isolated from an unvaccinated pediatric patient with exceptional plasma neutralization activity. EH3 and EH8 cross-neutralize the early VOCs and mediate strong Fc-dependent effector activity in vitro. Structural analyses of EH3 and EH8 in complex with the receptor-binding domain (RBD) revealed the molecular determinants of the epitope-driven protection and VOC-evasion. While EH3 represents the prevalent IGHV3-53 NAb whose epitope substantially overlaps with the ACE2 binding site, EH8 recognizes a narrow epitope exposed in both RBD-up and RBD-down conformations. When tested in vivo, a single-dose prophylactic administration of EH3 fully protected stringent K18-hACE2 mice from lethal challenge with Delta VOC. Our study demonstrates that protective NAbs responses converge in pediatric and adult SARS-CoV-2 patients.

microbiology↗

bioRxiv2019

Stag1 and Stag2 regulate cell fate decisions in hematopoiesis through non-redundant topological control

Transcriptional regulators, including the cohesin complex member STAG2, are recurrently mutated in cancer. The role of STAG2 in gene regulation, hematopoiesis, and tumor suppression remains unresolved. We show Stag2 deletion in hematopoietic stem/progenitor cells (HSPC) results in altered hematopoietic function, increased self-renewal, and impaired differentiation. ChIP-sequencing revealed that while Stag2 and Stag1 can bind the same loci, a component of Stag2 binding sites are unoccupied by Stag1 even in Stag2-deficient HSPCs. While concurrent loss of Stag2 and Stag1 abrogated hematopoiesis, Stag2 loss alone decreased chromatin accessibility and transcription of lineage-specification genes, including Ebf1 and Pax5, leading to blunted HSPC commitment to the B-cell lineage. Our data illustrate a role for Stag2 in transformation and transcriptional dysregulation distinct from its shared role with Stag1 in chromosomal segregation.\n\nOne Sentence SummaryStag1 rescues topologically associated domains in the absence of Stag2, but cannot restore chromatin architecture required for hematopoietic lineage commitment

cell biology↗

bioRxiv2018

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia: A report from the TARGET initiative

Acute myeloid leukemias (AML) are characterized by mutations of tumor suppressor and oncogenes, involving distinct genes in adults and children. While certain mutations have been associated with the increased risk of AML relapse, the genomic landscape of primary chemotherapy resistant AML is not well defined. As part of the TARGET initiative, we performed whole-genome DNA and transcriptome (RNA and miRNA) sequencing analysis of pediatric AML with failure of induction chemotherapy. We identified at least three genetic groups of patients with induction failure, including those with NUP98 rearrangements, somatic mutations of WT1 in the absence of NUP98 mutations, and additional recurrent variants including those in KMT2C and MLLT10. Comparison of specimens before and after chemotherapy revealed distinct and invariant gene expression programs. While exhibiting overt therapy resistance, these leukemias nonetheless showed diverse forms of clonal evolution upon chemotherapy exposure. This included selection for mutant alleles of FRMD8, DHX32, PIK3R1, SHANK3, MKLN1, as well as persistence of WT1 and TP53 mutant clones, and elimination or contraction of FLT3, PTPN11, and NRAS mutant clones. These findings delineate genetic mechanisms of primary chemotherapy resistance in pediatric AML, which should inform improved approaches for its diagnosis and therapy.

cancer biology↗

bioRxiv2018

Target variant detection in leukemia using unaligned RNA-Seq reads

Mutations identified in each Acute Myeloid Leukemia (AML) patients are useful for prognosis and to select targeted therapies. Detection of such mutations by the analysis of Next-Generation Sequencing (NGS) data requires a computationally intensive read mapping step and application of several variant calling methods. Targeted mutation identification drastically shifts the usual tradeoff between accuracy and performance by concentrating all computations over a small portion of sequence space. Here, we present km, an efficient approach leveraging k-mer decomposition of reads to identify targeted mutations. Our approach is versatile, as it can detect single-base mutations, several types of insertions and deletions, as well as fusions. We used two independent AML cohorts (The Cancer Genome Atlas and Leucegene), to show that mutation detection by km is fast, accurate and mainly limited by sequencing depth. Therefore, km allows to establish fast diagnostics from NGS data, and could be suitable for clinical applications.

bioinformatics↗